Stout served as exclusive financial advisor to CEFALY Technology in connection with its sale to DW Healthcare Partners, a healthcare private equity firm based in Toronto.
CEFALY, founded in 2004 and headquartered in Liège, Belgium, with operations in the U.S., is a world-leading manufacturer and distributor of proprietary, patent-protected neurostimulation medical devices under the CEFALY name for the treatment of migraine headaches. These products are non-invasive and self-applied by the patient to deliver electrical impulses to the trigeminal nerve, which is a superhighway to the center of the brain (central nervous system). The device is the only one of its kind that is approved by the Food and Drug Administration (FDA) and CE Mark and in active commercial use. The company’s clinical data has established the CEFALY devices among the most effective, safest, and consistent solution to alleviate acute migraine pain and the onset of migraine symptoms.